Program
risvutatug rezetecan
Also written as “HS-20093”, “HS-20093 for Injection” and “Risvutatug rezetecan (Ris-Rez)”.
In GlaxoSmithKline’s pipeline, ADC targeting B7-H3
. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Osteosarcoma · Neoplasms · Prostatic Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 2117 open or running | phase 3since Jul 6, 2024 | Feb 18, 2022 | Dec 30, 2026phase 1 · NCT06699576 |
| GlaxoSmithKline | 88 open or running | phase 3since Jul 30, 2025 | Mar 3, 2022 | Nov 5, 2027phase 3 · NCT07099898 |
| Jiangsu HengRui Medicine | 11 open or running | phase 2since Nov 13, 2025 | Nov 13, 2025 | Dec 2028phase 2 · NCT07230106 |
- Named in GlaxoSmithKline’s own pipeline as
risvutatug rezetecan GSK5764227
, phase 3, as of Sep 30, 2026 (source). - Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-20093 (B7-H3 ADC)
, phase 3, as of Aug 26, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Dec 20, 2023 · Source: GSK, Dec 20, 2023
How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.
Not listed one by one: 17 earlier studies, Feb 18, 2022 to Jul 30, 2025.
- Dec 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
- Aug 4, 2025Phase 1 study in Advanced Prostate CancerHansoh Pharmaceutical Group · NCT07115446 · 63 planned · China
- Sep 9, 2025Phase 1 study in Advanced Solid TumorsHansoh Pharmaceutical Group · NCT07186452 · 18 planned · China
- Nov 13, 2025Jiangsu HengRui Medicine’s first study: phase 2 study in Prostatic NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07230106 · 218 planned · China
- Dec 2, 2025Phase 1 study in NeoplasmsGlaxoSmithKline · NCT07277270 · 83 planned · United States, Australia, Canada and more
- Jan 15, 2026Phase 1 study in Advanced Gastric and Gastroesophageal Junction AdenocarcinomaHansoh Pharmaceutical Group · NCT07462923 · 40 enrolled · China
- Mar 6, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT07464327 · 450 planned
- May 11, 20262 phase 2 studiesGlaxoSmithKline · NCT07602777, NCT07602855
- May 26, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaHansoh Pharmaceutical Group · NCT07621601 · 494 planned
- Aug 13, 2026Phase 1 study in Small Cell Lung CarcinomaHansoh Pharmaceutical Group · NCT07892625 · 338 planned
- Aug 13, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT07824882 · 76 planned · China
- Aug 28, 2026Phase 3 study in Prostatic NeoplasmsGlaxoSmithKline · NCT07802704 · 684 planned · Australia, Canada, Japan and more
- Sep 25, 2026Primary completion moved from 2026-07-13 to 2028-02-14Date moved laterphase 1 · +19 months · NCT07277270
- Oct 19, 2026Primary completion moved from 2028-01-10 to 2029-01-09Date moved laterphase 2 · +12 months · NCT06885034
- Oct 20, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT07899086 · 102 planned
Ahead
- Dec 30, 2026Primary completion: phase 1 study in OsteosarcomaHansoh Pharmaceutical Group · NCT06699576
- Dec 31, 2026Primary completion: phase 1 study in Advanced Gastric and Gastroesophageal Junction AdenocarcinomaHansoh Pharmaceutical Group · NCT07462923
- Nov 5, 2027Primary completion: phase 2 study in SarcomaGlaxoSmithKline · NCT07602777
- Nov 5, 2027Primary completion: phase 3 study in Lung NeoplasmsGlaxoSmithKline · NCT07099898
TargetBeta
“ADC targeting B7-H3”the company's pipeline, read by Claude · source
“B7-H3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of risvutatug, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276) covalently ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ifinatamab deruxtecan | Merck | phase 3 | 16 |
| tambotatug pelitecan | MediLink Therapeutics (Suzhou) | phase 3 | 13 |
| Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 | CSPC Pharmaceutical Group | phase 3 | 5 |
| Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Minghui Pharmaceutical | phase 3 | 4 |
| Elfetabart Drozuntecanrule | BioNTech | phase 3 | 3 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01rule | radiopharm-theranostics-ltd | phase 2 | 1 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07899086Carcinoma, Non-Small-Cell Lung | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Dec 31, 2027 | 102 |
| NCT07802704Prostatic Neoplasms · Australia, Canada, Japan and more | 3 | Recruiting | GlaxoSmithKline | Dec 5, 2029 | 684 |
| NCT07892625Small Cell Lung Carcinoma | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Sep 15, 2028 | 338 |
| NCT07824882Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Hansoh Pharmaceutical Group | Mar 30, 2028 | 76 |
| NCT07621601Esophageal Squamous Cell Carcinoma | 3 | Not yet recruiting | Hansoh Pharmaceutical Group | Dec 31, 2030 | 494 |
| NCT07602855Lung Neoplasms · United States, Japan | 2 | Recruiting | GlaxoSmithKline | Jun 22, 2029 | 184 |
| NCT07602777Sarcoma · United States, Canada, France and more | 2 | Recruiting | GlaxoSmithKline | Nov 5, 2027 | 64 |
| NCT07464327Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | Hansoh Pharmaceutical Group | Dec 31, 2028 | 450 |
| NCT07462923Advanced Gastric and Gastroesophageal Junction Adenocarcinoma · China | 1 | Active, not recruiting | Hansoh Pharmaceutical Group | Dec 31, 2026 | 40 |
| NCT07277270Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | GlaxoSmithKline | Feb 14, 2028 | 83 |
| NCT07230106Prostatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2028 | 218 |
| NCT07186452Advanced Solid Tumors · China | 1 | Recruiting | Hansoh Pharmaceutical Group | Jul 31, 2026 | 18 |
| NCT07115446Advanced Prostate Cancer · China | 1 | Recruiting | Hansoh Pharmaceutical Group | Dec 2027 | 63 |
| NCT07099898Lung Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | GlaxoSmithKline | Nov 5, 2027 | 420 |
| NCT07063407Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Apr 30, 2026 | 50 |
| NCT06935409Osteosarcoma · China | 3 | Completed | Hansoh Pharmaceutical Group | Jun 17, 2026 | 122 |
| NCT06885034Gastrointestinal Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | GlaxoSmithKline | Jan 9, 2029 | 346 |
| NCT06825624Colorectal Neoplasms · China | 1 | Recruiting | Hansoh Pharmaceutical Group | Oct 31, 2026 | 560 |
| NCT06699576Osteosarcoma | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Dec 30, 2026 | 448 |
| NCT06551142Neoplasms · United States, Argentina, Canada and more | 1 | Recruiting | GlaxoSmithKline | Oct 16, 2028 | 845 |
| NCT06526624Small Cell Lung Carcinoma | 3 | Not yet recruiting | Hansoh Pharmaceutical Group | Nov 30, 2027 | 406 |
| NCT06498479Small Cell Lung Carcinoma · China | 3 | Completed | Hansoh Pharmaceutical Group | Aug 20, 2026 | 461 |
| NCT06332170Advanced Solid Tumor · China | 1 | Recruiting | Hansoh Pharmaceutical Group | May 30, 2026 | 610 |
| NCT06112704Esophageal Neoplasms · China | 2 | Recruiting | Hansoh Pharmaceutical Group | Jul 31, 2026 | 220 |
| NCT06052423Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 2 | Withdrawn | Hansoh Pharmaceutical Group | Jun 30, 2025 | 0 |
| NCT06007729Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Hansoh Pharmaceutical Group | Dec 12, 2025 | 170 |
| NCT06001255Metastasis Castration Resistant Prostate Cancer(mCRPC) · China | 2 | Recruiting | Hansoh Pharmaceutical Group | Dec 31, 2024 | 120 |
| NCT05830123Osteosarcoma · China | 2 | Recruiting | Hansoh Pharmaceutical Group | Dec 31, 2025 | 170 |
| NCT05277051Neoplasms · United States, Australia, Canada and more | 1 | Active, not recruiting | GlaxoSmithKline | Jun 30, 2026 | 152 |
| NCT05276609Advanced Solid Tumor · China | 1 | UNKNOWN | Hansoh Pharmaceutical Group | Dec 31, 2023 | 177 |
How it is read
Names in the registry
- “HS-20093”, 15 entries
- “HS-20093 for Injection”, 4 entries
- “Risvutatug rezetecan (Ris-Rez)”, 2 entries
- “GSK5764227”, 2 entries
- “Ris-Rez”, 2 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Osteosarcoma, 3 studies
- Neoplasms, 3 studies
- Prostatic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.